{
    "Trade/Device Name(s)": [
        "BD Phoenix Automated Microbiology System - Moxifloxacin 0.125-8 \u03bcg/mL - GP",
        "BD Phoenix Automated Microbiology System - Ciprofloxacin 0.25-4 \u03bcg/mL - GN",
        "BD PhoenixM Automated Microbiology System for use with the antimicrobial agent Moxifloxacin (0.125-8 \u03bcg/mL) and Ciprofloxacin (0.25-4 \u03bcg/mL) on ID/AST or AST panels"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K060217",
    "Predicate Device Reference 510(k) Number(s)": [
        "N50510",
        "K020321",
        "K031306",
        "K052269"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "April 12, 2006",
    "Summary Letter Received Date": "January 27, 2006",
    "Submission Date": "January 26, 2006",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility Devices"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Moxifloxacin",
        "Ciprofloxacin"
    ],
    "Specimen Type(s)": [
        "Pure culture isolates",
        "Most aerobic Gram-negative bacteria",
        "Facultative anaerobic Gram-negative bacteria",
        "Gram-positive bacteria"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Broth microdilution",
        "Redox indicator detection",
        "Automated susceptibility testing",
        "Measurement of bacterial turbidity"
    ],
    "Methodologies": [
        "Antimicrobial susceptibility testing",
        "Minimum inhibitory concentration (MIC) determination"
    ],
    "Submission Type(s)": [
        "System",
        "Instrument",
        "Panel",
        "Reagent",
        "Software",
        "Broth"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System for Moxifloxacin and Ciprofloxacin antimicrobial susceptibility testing in Gram-negative and Gram-positive bacterial isolates",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) for most Gram-negative and Gram-positive bacteria isolates from pure culture, including specific genera and species, using Moxifloxacin and Ciprofloxacin in BD Phoenix panels",
    "fda_folder": "Microbiology"
}